Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Karyopharm Therapeutics Company Profile (NASDAQ:KPTI)

Consensus Ratings for Karyopharm Therapeutics (NASDAQ:KPTI) (?)
Ratings Breakdown: 6 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $52.71 (36.74% upside)

Analysts' Ratings History for Karyopharm Therapeutics (NASDAQ:KPTI)
Show:
DateFirmActionRatingPrice TargetDetailsShare
11/10/2014OppenheimerUpgradeMarket Perform -> Outperform$53.00ViewTweet This Rating  Share This Rating on StockTwits
11/5/2014Barrington ResearchInitiated CoverageBuy$54.00ViewTweet This Rating  Share This Rating on StockTwits
11/5/2014MLV & Co Initiated CoverageBuy$54.00ViewTweet This Rating  Share This Rating on StockTwits
10/6/2014WedbushInitiated CoverageOutperform$50.00ViewTweet This Rating  Share This Rating on StockTwits
8/8/2014Leerink SwannLower Price Target$63.00 -> $60.00ViewTweet This Rating  Share This Rating on StockTwits
7/7/2014OppenheimerDowngradeOutperform -> Market PerformViewTweet This Rating  Share This Rating on StockTwits
3/20/2014RBC CapitalLower Price TargetViewTweet This Rating  Share This Rating on StockTwits
3/6/2014JMP SecuritiesBoost Price TargetOutperform$25.00 -> $50.00ViewTweet This Rating  Share This Rating on StockTwits
3/6/2014Bank of AmericaBoost Price TargetBuy$40.00 -> $48.00ViewTweet This Rating  Share This Rating on StockTwits
12/2/2013JMP SecuritiesInitiated CoverageOutperform$25.00ViewTweet This Rating  Share This Rating on StockTwits
12/2/2013Leerink SwannInitiated CoverageOutperformViewTweet This Rating  Share This Rating on StockTwits
12/2/2013Bank of AmericaInitiated CoverageBuy$24.00ViewTweet This Rating  Share This Rating on StockTwits
12/2/2013OppenheimerInitiated CoverageOutperform$23.00ViewTweet This Rating  Share This Rating on StockTwits
(Data available from 12/19/2012 forward)